ImmunoGen, Inc. (IMGN) News
Filter IMGN News Items
IMGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMGN News Highlights
- For IMGN, its 30 day story count is now at 18.
- Over the past 21 days, the trend for IMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- DRUG, ABBV and ASH are the most mentioned tickers in articles about IMGN.
Latest IMGN News From Around the Web
Below are the latest news stories about IMMUNOGEN INC that investors may wish to consider to help them evaluate IMGN as an investment opportunity.
3 Stocks at the Forefront of Medical InnovationBoring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. |
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's WhyThe acquisition fills an immediate need with some extras to boot. |
Are Investors Undervaluing ImmunoGen, Inc. (NASDAQ:IMGN) By 38%?Key Insights The projected fair value for ImmunoGen is US$47.87 based on 2 Stage Free Cash Flow to Equity Current share... |
The 7 Most Undervalued Growth Stocks to Buy in DecemberStocks of a lot of well-known and historically great companies are on sale right now. |
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For InvestorsIt's making a major acquisition to beef up a key area of its pipeline. |
While AbbVie Is Busy Investing in Growth, How Tradable Is it?Remember AbbVie ? On November 30, AbbVie announced plans to acquire ImmunoGen in a roughly $10.1B all-cash transaction. ImmunoGen already manufactures and markets Elahere, which is an antibody-drug conjugate, in fact the first of its kind approved for the treatment of platinum-resistant ovarian cancer. |
The 3 Best Cheap Stocks to Buy in DecemberInvestors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately. |
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASHWALTHAM, Mass., December 10, 2023--ImmunoGen Presents Findings from Newly Diagnosed AML Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Azacitidine and Venetoclax at ASH |
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?AbbVie's share price reflected the concerns. AbbVie's executives and business development team have been quite busy lately. On Nov. 30, AbbVie announced its plans to acquire ImmunoGen (NASDAQ: IMGN) in an all-cash transaction valued at roughly $10.1 billion. |
Market Movers: Why Big Players Are Investing Millions in These 3 StocksIn investing, certain stocks catch the discerning eye of big players, drawing in substantial investments. |